Pencik J, Philippe C, Schlederer M, Atas E, Pecoraro M, Grund-Groschke S
Mol Cancer. 2023; 22(1):133.
PMID: 37573301
PMC: 10422794.
DOI: 10.1186/s12943-023-01825-8.
Li H, Qiu L, Liu Q, Ma Z, Xie X, Luo Y
Genes (Basel). 2022; 13(9).
PMID: 36140747
PMC: 9498467.
DOI: 10.3390/genes13091579.
Zhu Z, Fang C, Xu H, Yuan L, Du Y, Ni Y
Front Oncol. 2022; 12:976557.
PMID: 36046036
PMC: 9423707.
DOI: 10.3389/fonc.2022.976557.
Taghavi B, Alizadeh N, Saeedi H, Ahangar N, Derakhshani A, Hajiasgharzadeh K
Molecules. 2022; 27(11).
PMID: 35684481
PMC: 9182385.
DOI: 10.3390/molecules27113545.
Parakh S, Ernst M, Poh A
Cancers (Basel). 2021; 13(24).
PMID: 34944848
PMC: 8699548.
DOI: 10.3390/cancers13246228.
NT157 Inhibits HCC Migration via Downregulating the STAT3/Jab1 Signaling Pathway.
Yu S, Wang Y, Lv K, Hou J, Li W, Wang X
Technol Cancer Res Treat. 2021; 20:15330338211027916.
PMID: 34238066
PMC: 8274079.
DOI: 10.1177/15330338211027916.
Cytosolic delivery of peptidic STAT3 SH2 domain inhibitors.
Cerulli R, Shehaj L, Tosic I, Jiang K, Wang J, Frank D
Bioorg Med Chem. 2020; 28(12):115542.
PMID: 32503696
PMC: 7294595.
DOI: 10.1016/j.bmc.2020.115542.
Trichothecin Inhibits Cancer-Related Features in Colorectal Cancer Development by Targeting STAT3.
Qi X, Li M, Zhang X, Dai X, Cui J, Li D
Molecules. 2020; 25(10).
PMID: 32422984
PMC: 7287781.
DOI: 10.3390/molecules25102306.
The JAK2/STAT3 pathway inhibitor, AG490, suppresses the abnormal behavior of keloid fibroblasts in vitro.
Zhou Y, Sun Y, Hou W, Ma L, Tao Y, Li D
Int J Mol Med. 2020; 46(1):191-200.
PMID: 32377718
PMC: 7255460.
DOI: 10.3892/ijmm.2020.4592.
LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
Pan L, Chen X, Fu S, Yu W, Li C, Wang T
Breast Cancer Res Treat. 2020; 181(1):31-41.
PMID: 32240456
DOI: 10.1007/s10549-020-05613-6.
Phosphotyrosine isosteres: past, present and future.
Cerulli R, Kritzer J
Org Biomol Chem. 2019; 18(4):583-605.
PMID: 31777907
PMC: 7233463.
DOI: 10.1039/c9ob01998g.
Hunting for transcription factors: STAT3 decoy in non-small cell lung cancer.
Carmicheal J, Kaur S, Batra S, Ganti A
Transl Lung Cancer Res. 2018; 7(Suppl 3):S254-S257.
PMID: 30393616
PMC: 6193924.
DOI: 10.21037/tlcr.2018.09.06.
STAT3 promotes tumour progression in glioma by inducing FOXP1 transcription.
Sun X, Wang J, Huang M, Chen T, Chen J, Zhang F
J Cell Mol Med. 2018; 22(11):5629-5638.
PMID: 30134017
PMC: 6201216.
DOI: 10.1111/jcmm.13837.
STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non-Small Cell Lung Cancer.
Njatcha C, Farooqui M, Kornberg A, Johnson D, Grandis J, Siegfried J
Mol Cancer Ther. 2018; 17(9):1917-1926.
PMID: 29891486
PMC: 6125196.
DOI: 10.1158/1535-7163.MCT-17-1194.
Biochemical Properties of a Decoy Oligodeoxynucleotide Inhibitor of STAT3 Transcription Factor.
Lee D, OKeefe R, Ha P, Grandis J, Johnson D
Int J Mol Sci. 2018; 19(6).
PMID: 29848966
PMC: 6032396.
DOI: 10.3390/ijms19061608.
Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy.
Xiao H, Bid H, Chen X, Wu X, Wei J, Bian Y
PLoS One. 2017; 12(7):e0180297.
PMID: 28672024
PMC: 5495564.
DOI: 10.1371/journal.pone.0180297.
Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling.
Wang Y, Ma H, Zhao C, Liu T, Yan D, Jou D
Oncotarget. 2017; 8(20):33683-33693.
PMID: 28430601
PMC: 5464902.
DOI: 10.18632/oncotarget.16898.
Role of STAT3 in Genesis and Progression of Human Malignant Gliomas.
Ouedraogo Z, Biau J, Kemeny J, Morel L, Verrelle P, Chautard E
Mol Neurobiol. 2016; 54(8):5780-5797.
PMID: 27660268
DOI: 10.1007/s12035-016-0103-0.
Stat3 contributes to cancer progression by regulating Jab1/Csn5 expression.
Pan Y, Wang S, Su B, Zhou F, Xu T, Zhang R
Oncogene. 2016; 36(8):1069-1079.
PMID: 27524414
PMC: 5311075.
DOI: 10.1038/onc.2016.271.
Inhibition of STAT3 enhances the radiosensitizing effect of temozolomide in glioblastoma cells in vitro and in vivo.
Han T, Cho B, Choi E, Kim D, Song S, Paek S
J Neurooncol. 2016; 130(1):89-98.
PMID: 27510952
DOI: 10.1007/s11060-016-2231-9.